推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

CANCER LETTERS

2024年6月最新影响因子数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 CANCER LETT最新评论:审稿速度:1.0 | 投稿命中率:50.0偏重的研究方向:肿瘤;耐药机制经验分享:05.22 submitted to journal05.22 with editor 05... (2024-10-23)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中国科学院分区:   是否OA期刊:   结果排序:
 
同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


CANCER LETTERS期刊基本信息Hello,您是该期刊的第332747位访客


基本信息 登录收藏
期刊名字CANCER LETTERSCANCER LETTERS

CANCER LETT
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
9.0
60人评分
我要评分

声誉
9.8

影响力
8.2

速度
9.2

期刊ISSN0304-3835
微信扫码收藏此期刊
E-ISSN1872-7980
2023-2024最新影响因子
(数据来源于搜索引擎)
9.1 点击查看影响因子趋势图
实时影响因子 截止2024年10月29日:7.556
2023-2024自引率6.60%点击查看自引率趋势图
五年影响因子8.3
JCI期刊引文指标 1.98
h-index 161
CiteScore
2024年最新版
CiteScoreSJRSNIPCiteScore排名
17.702.5951.470
学科分区排名百分位
大类:Medicine
小类:Oncology
Q126 / 404
大类:Medicine
小类:Cancer Research
Q119 / 230

期刊简介
CANCER LETTERS is a journal providing rapid publication of full-length articles in the broad area of cancer research. The journal places emphasis on the molecular and cell biology of cancer, oncogenes, carcinogenesis, radiation biology, molecular pathology, hormones and cancer, viral oncology, biology of cancer and metastasis, molecular cytogenetics, epidemiology; and experimental therapeutics. The primary criterion for publication is interest to a multidisciplinary audience. Papers should be technically sound and substantiated by sufficient experimental detail. Clinical papers will be accepted if they contribute to the understanding of the basic mechanisms underlying disease.
期刊官方网站https://www.journals.elsevier.com/cancer-letters
期刊投稿网址https://www.editorialmanager.com/CANLET
期刊语言要求Language
Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English Language Editing service.

经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足CANCER LETTERS的语言要求,还能让CANCER LETTERS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被CANCER LETTERS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评(1篇) 论文致谢(6篇)
提交文稿
是否OA开放访问No
通讯方式ELSEVIER IRELAND LTD, ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, IRELAND, 00000
出版商Elsevier Ireland Ltd
涉及的研究方向医学-肿瘤学
出版国家或地区NETHERLANDS
出版语言English
出版周期Biweekly
出版年份1975
年文章数 279点击查看年文章数趋势图
Gold OA文章占比28.32%
研究类文章占比:
文章 ÷(文章 + 综述)
98.21%
WOS期刊SCI分区
2023-2024年最新版
WOS分区等级:1区

按JIF指标学科分区收录子集JIF分区JIF排名JIF百分位
学科:ONCOLOGYSCIEQ133/322
按JCI指标学科分区收录子集JCI分区JCI排名JCI百分位
学科:ONCOLOGYSCIEQ131/322
中国科学院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
中国科学院SCI期刊分区
2023年12月最新升级版
点击查看中国科学院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 2区1区1区
ONCOLOGY
肿瘤学
3区1区2区
中国科学院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 4区1区3区
ONCOLOGY
肿瘤学
3区2区2区
中国科学院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 4区1区4区
ONCOLOGY
肿瘤学
1区4区2区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0304-3835%5BISSN%5D
平均审稿速度网友分享经验:
平均2.7个月
来源Elsevier官网:
平均3.3周
平均录用比例网友分享经验:
约52.27%
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在CANCER LETTERS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
在线出版周期来源Elsevier官网:
平均8.3周
期刊常用信息链接
同领域相关期刊 CANCER LETTERS期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 CANCER LETTERS中国科学院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
CANCER LETTERS上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中国科学院分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 中国科学院分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    Nature Reviews Clinical Oncology12799.40
    NATURE REVIEWS CANCER396111.90
    ANNALS OF ONCOLOGY21063.90
    CANCER CELL29555.20
    JOURNAL OF CLINICAL ONCOLOGY49441.20
    LANCET ONCOLOGY27462.10
    CANCER RESEARCH41116.10
    SEMINARS IN CANCER BIOLOGY13426.80
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH6718.20
    中国科学院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE677700
    BIOMATERIALS567285
    BIOMEDICINE & PHARMACOTHERAPY552018
    Frontiers in Pharmacology515786
    Journal of Materials Chemistry B506974
    Frontiers in Immunology492571
    COMPUTERS IN BIOLOGY AND MEDICINE474436
    JOURNAL OF ETHNOPHARMACOLOGY466711
    COLLOIDS AND SURFACES B-BIOINTERFACES438831
    Frontiers in Oncology436521
  •  

    CANCER LETTERS CANCER LETTERS
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Patient-derived organoids in translational oncology and drug screening

    Author: Yang, Ruixin; Yu, Yingyan
    Journal: CANCER LETTERS. 2023; Vol. 562, Issue , pp. -. DOI: 10.1016/j.canlet.2023.216180
        PubMed      DOI
    2.PIWI-interacting RNAs: Critical roles and therapeutic targets in cancer

    Author: Zhou, Jialin; Xie, Han; Liu, Jun; Huang, Ruixiang; Xiang, Yufei; Tian, Dasheng; Bian, Erbao
    Journal: CANCER LETTERS. 2023; Vol. 562, Issue , pp. -. DOI: 10.1016/j.canlet.2023.216189
        PubMed      DOI
    3.Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions

    Author: Zhang, Chenyue; Zhang, Chenxing; Wang, Haiyong
    Journal: CANCER LETTERS. 2023; Vol. 562, Issue , pp. -. DOI: 10.1016/j.canlet.2023.216182
        PubMed      DOI
    4.Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers

    Author: Shi, Fukang; Huang, Xing; Hong, Zhengtao; Lu, Na; Huang, Xin; Liu, Lingyue; Liang, Tingbo; Bai, Xueli
    Journal: CANCER LETTERS. 2023; Vol. 562, Issue , pp. -. DOI: 10.1016/j.canlet.2023.216167
        PubMed      DOI
    5.Ultrasound-excited temozolomide sonosensitization induces necroptosis in glioblastoma

    Author: Wang, Fanchen; Xu, Lixia; Wen, Binli; Song, Sirong; Zhou, Yan; Wu, Haiyang; Wu, Qiaoli; Wang, Yinsong; Tong, Xiaoguang; Yan, Hua
    Journal: CANCER LETTERS. 2023; Vol. 554, Issue , pp. -. DOI: 10.1016/j.canlet.2022.216033
        PubMed      DOI
    6.Gut microbiota and colorectal cancer metastasis

    Author: Zheng, Zongmei; Hou, Xinxin; Bian, Zhaoxiang; Jia, Wei; Zhao, Ling
    Journal: CANCER LETTERS. 2023; Vol. 555, Issue , pp. -. DOI: 10.1016/j.canlet.2022.216039
        PubMed      DOI
    7.SHP2 inhibition mitigates adaptive resistance to MEK inhibitors in KRAS-mutant gastric cancer through the suppression of KSR1 activity

    Author: Zheng, Wenfang; Yang, Zhiyi; Song, Ping; Sun, Yingchao; Liu, Pan; Yue, Lei; Lv, Kaiqi; Wang, Xinjie; Shen, Yuqin; Si, Jianmin; Zhang, Xue; Ke, Yuehai; Cheng, Hongqiang; Hu, Weiling
    Journal: CANCER LETTERS. 2023; Vol. 555, Issue , pp. -. DOI: 10.1016/j.canlet.2022.216029
        PubMed      DOI
    8.Immune checkpoint inhibitor resistance in hepatocellular carcinoma

    Author: Wang, Zhijie; Wang, Yichuan; Gao, Peng; Ding, Jin
    Journal: CANCER LETTERS. 2023; Vol. 555, Issue , pp. -. DOI: 10.1016/j.canlet.2022.216038
        PubMed      DOI
    9.5-ALA mediated photodynamic therapy with combined treatment improves anti-tumor efficacy of immunotherapy through boosting immunogenic cell death

    Author: Sun, Zhuoran; Zhao, Mingyi; Wang, Weibi; Hong, Lanhui; Wu, Zhongguang; Luo, Guang; Lu, Siyao; Tang, Yueyue; Li, Jiehan; Wang, Jiangang; Zhang, Yingjie; Zhang, Lingling
    Journal: CANCER LETTERS. 2023; Vol. 554, Issue , pp. -. DOI: 10.1016/j.canlet.2022.216032
        PubMed      DOI
    10.Sex steroid axes in determining male predominance in hepatocellular carcinoma

    Author: Zhang, Lei; Wu, JinFeng; Wu, QiuMei; Zhang, XiangJuan; Lin, ShuaiCai; Ran, WanLi; Zhu, Li; Tang, ChengYan; Wang, Xing
    Journal: CANCER LETTERS. 2023; Vol. 555, Issue , pp. -. DOI: 10.1016/j.canlet.2022.216037
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Disease Primers4876.70
    NATURE REVIEWS CANCER396111.90
    NATURE REVIEWS IMMUNOLOGY35193.40
    同分区等级的其他期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144873.20
    NATURE REVIEWS DRUG DISCOVERY289137.40
    LANCET700148.10
    NEW ENGLAND JOURNAL OF MEDICINE933145.40
    BMJ-British Medical Journal019.90
    BMJ-British Medical Journal019.90
    NATURE REVIEWS MOLECULAR CELL BIOLOGY386173.60
    Nature Reviews Clinical Oncology12799.40
    Nature Reviews Materials61119.40
    Nature Reviews Disease Primers4876.70
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

同领域作者分享投稿经验:共1439


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室